The Street almost seems to be processing the quarterly reports from Big Pharma companies like Bristol-Myers Squibb and Pfizer (NYSE: PFE )
as annoying opening acts that just have to be tolerated before the
headliner goes on stage. With that in mind, Pfizer's decent fourth
quarter results aren't likely to matter as much as upcoming clinical
trial results from studies of palbociclib ("palbo"), Prevnar, and
Xeljanz that could collectively point the way toward over $10 billion in
long-term revenue.
Continue reading here:
Pfizer Inc. Treading Water Ahead Of Clinical Data
No comments:
Post a Comment